AbbVie's Upadacitinib Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis

ABBVie today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis showing upadacitinib met the primary endpoint of Assessment in SpondyloArthritis International Society 40 response and the majority of ranked secondary endpoints at week 14. 1 Significantly more upadacitinib-treated patients achieved ASAS40 ...

Related Keywords

Oregon ,United States ,Japan ,Japanese ,Michael Severino ,Twitter ,European Commission ,Drug Administration ,Rheumatic Diseases At Oregon Health Science University ,Exchange Commission ,Spondyloarthritis Research Consortium Of Canada ,Assessment In Spondyloarthritis International Society ,Allergan ,Facebook ,Abbvie Deutschland Gmbh Co ,Rheumatology Clinics For The Division Of Arthritis ,Spondyloarthritis International Society ,Ankylosing Spondylitis ,Disease Activity ,Low Disease Activity ,Magnetic Resonance Imaging ,Spondyloarthritis Research Consortium ,Total Back Pain ,Bath Ankylosing Spondylitis Functional Index ,Efficacy Results ,Atul Deodhar ,Rheumatology Clinics ,Rheumatic Diseases ,Oregon Health ,Axial Spondyloarthritis ,Important Safety Information About ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Psoriatic Arthritis ,Inadequate Response ,Week Data ,Randomized Controlled Phase ,Vie Deutschland Gmbh ,Evaluate Efficacy ,Adult Participants With Axial Spondyloarthritis ,Maintenance Therapy ,Subjects With Moderately ,Severely Active Ulcerative ,Compare Safety ,Adult Participants With Moderate ,Severe Atopic Dermatitis ,Participants With Moderately ,Severely Active Ulcerative Colitis ,Placebo Controlled Study ,Endoscopic Remission ,Severely Active Crohn ,Disease Who Have Inadequately Responded ,Are Intolerant ,Participants With Giant Cell Arteritis ,Subjects With Takayasu Arteritis ,Understanding Axial Spondyloarthritis ,